Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
Celldex Therapeutics (NASDAQ:CLDX) will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on March 30, 2023, at 11:30 am ET. The event will be accessible via a webcast on the company's website, with a replay available for 90 days post-event. Celldex is a clinical-stage biotechnology firm focusing on developing monoclonal and bispecific antibodies to treat severe diseases. Their innovative therapeutics aim to engage the immune system or target critical pathways, enhancing treatment options for patients with inflammatory diseases and various cancers.
- None.
- None.
HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30th at 11:30 am ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.
About Celldex Therapeutics, Inc.
Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer. Visit www.celldex.com.
Company Contact
Sarah Cavanaugh
Senior Vice President, Corporate Affairs & Administration
(508) 864-8337
scavanaugh@celldex.com
Patrick Till
Meru Advisors
(484) 788-8560
ptill@meruadvisors.com
FAQ
When is the Celldex Therapeutics fireside chat at the H.C. Wainwright Conference?
How can I access the Celldex Therapeutics conference presentation?
Will there be a replay of the Celldex conference presentation?